ArticleAnnals of hematology2026
Outcomes of hematopoietic stem cell transplantation in adult sickle cell disease patients: A Single-Center experience from India.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sickle cell disease (SCD) in adults remains a significant clinical challenge, with limited curative options and high morbidity and mortality. Hematopoietic stem cell transplantation (HSCT) offers a potential cure, yet data on its feasibility and outcomes in adults, particularly from low- and middle-income countries, remain scarce. This retrospective single-centre study reports outcomes of HSCT in 14 adult SCD patients treated between 2018 and 2024 in India—the largest such series from South-East Asia. Patients underwent either matched sibling donor (MSD, n = 9) or haploidentical (Haplo, n = 5) transplants following myeloablative conditioning. All patients had high symptom burden, including ≥ 2 vaso-occlusive crises annually. Median follow-up was 22.4 months. Event-free survival (EFS) and overall survival (OS) were 71.4% and 78.6%, respectively. Full or mixed donor chimerism was achieved in 84.6% of patients. Notably, patients achieving chimerism reported no sickle-related events post-transplant. Acute GVHD occurred in 6 patients, all grade ≤ 2; no grade 3/4 GVHD or GVHD-related mortality was observed. Cytomegalovirus reactivation and posterior reversible encephalopathy syndrome (PRES) were manageable with standard interventions. This study demonstrates that HSCT in symptomatic adult SCD patients is both feasible and effective in resource-constrained settings when conducted in specialized centers with multidisciplinary support. These findings challenge the historical reluctance to offer HSCT to adults with SCD and underscore the urgent need for accessible curative options in this population. Policy reforms, expanded transplant access, and early referral pathways are vital to improving outcomes in adult SCD across similar healthcare settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.